Trials / Completed
CompletedNCT04519658
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 275 (actual)
- Sponsor
- CinCor Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CIN-107 | CIN-107 tablets by mouth once daily |
| DRUG | Placebo | placebo tablets by mouth once daily |
Timeline
- Start date
- 2020-10-12
- Primary completion
- 2022-06-14
- Completion
- 2022-06-14
- First posted
- 2020-08-20
- Last updated
- 2023-07-24
- Results posted
- 2023-06-28
Locations
80 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04519658. Inclusion in this directory is not an endorsement.